Zithromax Patent Expiration

Zithromax is a drug owned by Pfizer Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 31, 2018. Details of Zithromax's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6268489 Azithromycin dihydrate
Jul, 2018

(8 years ago)

Expired


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Zithromax and ongoing litigations to help you estimate the early arrival of Zithromax generic.

Zithromax's Litigations

Zithromax been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US6268489. The petitioner , challenged the validity of this patent, with ALLEN et al as the respondent. Click below to track the latest information on how companies are challenging Zithromax's patents.

Last updated on October 13, 2026
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6268489 January, 1 Decision
(15 Apr, 1998)
ALLEN et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zithromax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zithromax's family patents as well as insights into ongoing legal events on those patents.

Zithromax's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Clinical Trials

Recent Clinical Trials on Zithromax:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction Sanofi NA RECRUITING
(Sep 1, 2026)
PHASE3
Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants Assistance Publique - Hôpitaux de Paris NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial Johns Hopkins University NA COMPLETED
(Aug 1, 2026)
PHASE3
Single Dose Azithromycin to Prevent Cholera in Children Massachusetts General Hospital NA COMPLETED
(Aug 1, 2026)
PHASE2
An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM Queen Mary University of London NA COMPLETED
(Aug 1, 2026)
PHASE3
Azithromycin for Critical Asthma - Pediatrics Johns Hopkins All Children's Hospital NA RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3
Effectiveness of Epigallocatechin-3-Gallate (Green Tea Extract) as Adjunctive Locally Delivered Nanotherapeutic in the Treatment of Stage II Periodontitis Mansoura University NA RECRUITING
(Aug 1, 2026)
PHASE1
Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease Rambam Health Care Campus NA RECRUITING
(Jul 1, 2026)
PHASE2
Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws) Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia NA COMPLETED
(Jul 1, 2026)
PHASE3
AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth Assistance Publique Hopitaux De Marseille NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE3
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Jun 4, 2026)
PHASE1, PHASE2
Sanitation, Water, and Instruction in Face-washing for Trachoma I/II University of California, San Francisco NA COMPLETED
(Jun 1, 2026)
PHASE3
Azithromycin for Meningococcal Carriage Emory University NA COMPLETED
(Jun 1, 2026)
PHASE2
A Study of Standard Drugs for Mycobacterium Avium Complex Johns Hopkins University NA COMPLETED
(May 1, 2026)
PHASE2
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment The University of Queensland NA RECRUITING
(May 1, 2026)
PHASE2, PHASE3
Assessing the Impact of Unnecessary Antibiotic Treatment on the Development of Appropriate Adaptive Immune Responses in Malnourished Bangladeshi Infants University of Virginia NA NOT YET RECRUITING
(May 1, 2026)
PHASE1
Tocilizumab Treatment in Patients With COVID-19 Instituto Nacional de Cancerologia de Mexico NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial The George Washington University Biostatistics Center NA RECRUITING
(Apr 1, 2026)
PHASE3
Antibiotic Treatment of Recurrent Episodes of Asthma in Children Copenhagen Studies on Asthma in Childhood NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2
Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts Washington University School of Medicine NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis University Hospital, Toulouse NA COMPLETED
(Mar 1, 2026)
PHASE3
Improving Care Through Azithromycin Research for Infants in Africa Barcelona Institute for Global Health NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 University of Oklahoma NA RECRUITING
(Mar 1, 2026)
PHASE2
The Impact of Shigellosis and Recommended Treatment in Children Johns Hopkins Bloomberg School of Public Health NA RECRUITING
(Mar 1, 2026)
PHASE2




Generic Launch

Generic Release Date:

Zithromax's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 31, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zithromax Generic API suppliers:

Azithromycin is the generic name for the brand Zithromax. 32 different companies have already filed for the generic of Zithromax, with Chartwell Rx having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zithromax's generic

Alternative Brands for Zithromax

There are several other brand drugs using the same active ingredient (Azithromycin) as Zithromax. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Pf Prism Cv
Zmax
Thea Pharma
Azasite


Apart from brand drugs containing the same ingredient, some generics have also been filed for Azithromycin, Zithromax's active ingredient. Check the complete list of approved generic manufacturers for Zithromax





About Zithromax

Zithromax is a drug owned by Pfizer Inc. Zithromax uses Azithromycin as an active ingredient. Zithromax was launched by Pfizer in 2002.

Approval Date:

Zithromax was approved by FDA for market use on 24 May, 2002.

Active Ingredient:

Zithromax uses Azithromycin as the active ingredient. Check out other Drugs and Companies using Azithromycin ingredient

Dosage:

Zithromax is available in the following dosage forms - tablet form for oral use, for suspension form for oral use, injectable form for injection use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 500MG BASE TABLET Prescription ORAL
EQ 250MG BASE TABLET Prescription ORAL
EQ 600MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
EQ 100MG BASE/5ML FOR SUSPENSION Prescription ORAL
EQ 200MG BASE/5ML FOR SUSPENSION Prescription ORAL
EQ 1GM BASE/PACKET FOR SUSPENSION Discontinued ORAL
EQ 500MG BASE/VIAL INJECTABLE Discontinued INJECTION